# GENFIT: NASHnext®, Powered by GENFIT's Non-invasive Diagnostic Technology NIS4®, Launched via Labcorp’s OnDemand Offering for Identification of At-Risk MASH
Canonical URL: https://biopharmsignal.com/news/GNFT/genfit-nashnextr-powered-by-genfit-s-non-invasive-diagnostic-technology-nis4r-launched-via-labcorp-s-ondemand-offering-for-identification-of-at-risk-mash
Ticker: GNFT
Company: GENFIT
Source: GENFIT
Published: 2026-06-25 13:46 EST
Original Source URL: https://ir.genfit.com
## Summary

Labcorp OnDemand enables convenient testing with the NASHnext® test, within a physician-directed care pathway to support identification of patients with at-risk MASH This model expands access and supports adoption of NASHnext®, enabling testing across a wider patient population Lille (France),

## Article Body
Labcorp OnDemand enables convenient testing with the NASHnext® test, within a physician-directed care pathway to support identification of patients with at-risk MASH This model expands access and supports adoption of NASHnext®, enabling testing across a wider patient population Lille (France),
## Recent Company News
- 2026-07-02 16:05 EST — [GENFIT Announces U.S. Medicare Coverage and Future Reimbursement for NASHnext®, a Non-Invasive Diagnostic Technology to Identify Patients with At-Risk MASH](https://biopharmsignal.com/news/GNFT/genfit-announces-u-s-medicare-coverage-and-future-reimbursement-for-nashnext-a-n-2769741e) — Source: GENFIT
- 2026-06-25 13:46 EST — [GENFIT: Positive Phase 1b Data with GNS561 in Combination Therapy in Heavily Pretreated Patients with Cholangiocarcinoma](https://biopharmsignal.com/news/GNFT/genfit-positive-phase-1b-data-with-gns561-in-combination-therapy-in-heavily-pretreated-patients-with-cholangiocarcinoma) — Source: GENFIT
- 2026-06-25 13:46 EST — [GENFIT: June 15, 2026 Combined Shareholders Meeting Results](https://biopharmsignal.com/news/GNFT/genfit-june-15-2026-combined-shareholders-meeting-results) — Source: GENFIT
- 2026-06-25 13:46 EST — [GENFIT: NASHnext®, Powered by GENFIT's Non-invasive Diagnostic Technology NIS4®, Launched via Labcorp’s OnDemand Offering for Identification of At-Risk MASH](https://biopharmsignal.com/news/GNFT/genfit-nashnextr-powered-by-genfit-s-non-invasive-diagnostic-technology-nis4r-launched-via-labcorp-s-ondemand-offering-for-identification-of-at-risk-mash) — Source: GENFIT
- 2026-06-25 13:46 EST — [GENFIT Highlights Broad Scientific and Strategic Presence at EASL Congress 2026](https://biopharmsignal.com/news/GNFT/genfit-highlights-broad-scientific-and-strategic-presence-at-easl-congress-2026) — Source: GENFIT
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)